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Abstract
Animal studies point to an implication of the endocannabinoid system on executive functions. In humans, several studies
have suggested an association between acute or chronic use of exogenous cannabinoids (D9-tetrahydrocannabinol) and
executive impairments. However, to date, no published reports establish the relationship between endocannabinoids, as
biomarkers of the cannabinoid neurotransmission system, and executive functioning in humans. The aim of the present
study was to explore the association between circulating levels of plasma endocannabinoids N-arachidonoylethanolamine
(AEA) and 2-Arachidonoylglycerol (2-AG) and executive functions (decision making, response inhibition and cognitive
flexibility) in healthy subjects. One hundred and fifty seven subjects were included and assessed with the Wisconsin Card
Sorting Test; Stroop Color and Word Test; and Iowa Gambling Task. All participants were female, aged between 18 and 60
years and spoke Spanish as their first language. Results showed a negative correlation between 2-AG and cognitive
flexibility performance (r =2.37; p,.05). A positive correlation was found between AEA concentrations and both cognitive
flexibility (r = .59; p,.05) and decision making performance (r = .23; P,.05). There was no significant correlation between
either 2-AG (r =2.17) or AEA (r =2.08) concentrations and inhibition response. These results show, in humans, a relevant
modulation of the endocannabinoid system on prefrontal-dependent cognitive functioning. The present study might have
significant implications for the underlying executive alterations described in some psychiatric disorders currently associated
with endocannabinoids deregulation (namely drug abuse/dependence, depression, obesity and eating disorders).
Understanding the neurobiology of their dysexecutive profile might certainly contribute to the development of new
treatments and pharmacological approaches.
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Introduction
Cannabis has been used for thousands of years and has long
been associated with effects on cognitive and emotional processes.
Investigation over the last decades has revealed that the effects of
cannabinoids are mediated by their action on the endocannabi-
noid system. The endocannabinoid system comprises two recep-
tors (CB1 and CB2) found predominately on presynaptic terminals
of glutamatergic and GABAergic neurons [1]. The cannabinoid
receptor 1 (CB1) is the most widely expressed G-protein coupled
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receptor in the brain and is associated with the majority of central
effects of the cannabinoids [2]. Endogenous cannabinoid ligands
(endocannabinoids) bind to cannabinoid receptors, and up to now,
the arachidonate-derived lipid molecules N-arachidonoylethano-
lamine (anandamide; AEA) [3] and 2-arachidonoylglycerol (2-AG)
[4] are the best studied and are considered as retrograde
messengers in the brain.
The biosynthesis of endocannabinoids in the brain has been
reviewed by Di Marzo [5]. Unlike the typical neurotransmitters,
endocannabinoids are stored in the membrane as phospholipid
precursors and released ‘‘on demand’’ by the elevation of
intracellular Ca2+, membrane depolarization, or stimulation of
metabotropic receptors. The endocannabinoids AEA and 2-AG
are biosynthesized from different membrane phospholipid fami-
lies, both esterified with arachidonic acid. For example, N-
arachidonoylethanolamide, AEA is produced from N-arachido-
noylphosphatidylethanolamines (NArPE). Several possible biosyn-
thetic routes for the formation of AEA have been suggested with
multiple enzymes implicated: the N-acylphosphatidylethanola-
mine specific phospholipase D (NAPE-PLD), the a,b-Hydrolase-4
(ABHD4), the glycerophosphodiesterase-1 (GDE1), a soluble
phospholipase A2, an unidentified phospholipase C, and phos-
phatases. These biosynthetic pathways may be able to substitute
one another as mice lacking NAPE-PLD do not show decreased
AEA [6]. AEA is generally degraded by the fatty acid amide
hydrolase (FAAH) enzyme [7]. Additionally, AEA can be
degraded by two other enzymes, FAAH-2 and N-acylethanola-
mine acid amidase [8]. In contrast, the biosynthetic precursors for
2-AG, the sn-1-acyl-2-arachidonoylglycerols (AArG) are mostly
produced by phospholipase Cb (PLCb) acting on membrane
phosphatidylinositols, and then converted to 2-AG by the action of
either of two isoforms of the same enzyme, the sn-1-diacylglycerol
lipases a and b (DAGLa and DAGLb) [9]. 2-AG is largely
degraded by the monoacylglycerol lipase (MAGL) [7].
A network of interactions between the biosynthetic pathways of
the two main brain endocannabinoids AEA and 2-AG has been
suggested [5]: (i) the formation of their phospholipid precursors is
dependent on the pool of arachidonic acid available; (ii) the
degradation of AEA and 2-AG releases in both cases free
arachidonic acid which can be rapidly re-esterified into phospho-
lipids; (iii) in brain, 2-AG levels are approximately 200 times
higher than AEA and the hydrolysis of 2-AG by MAGL
contributes to determining free arachidonic acid levels, unlike
anandamide hydrolysis [10].
The endocannabinoid system has been implicated in different
behaviors, including food intake [11], the reinforcing character-
istics of drugs of abuse [12] and cognitive processing [13–15]. The
role of the endocannabinoid system in memory functioning has
been widely studied [13,14], apparently because of the high
density of CB1 receptors in the hippocampus [16]. However, the
endocannabinoid system appears to be implicated in other
prefrontal-mediated cognitive functions such as the executive
functions [17]. A major role of the endocannabinoid system in
prefrontal activity was originally suggested by the elevated number
of CB1 in this cerebral region, observed in both animals [18,19]
and humans [20]. Additionally, the endocannabinoids AEA and 2-
AG are also found in this brain area [21], as well as the fatty acid
amide hydrolase (FAAH) and monoacylglycerol Lipase (MAGL)
[22], the enzymes accountable for AEA and 2-AG degradation
[23,24].
The effects of the endocannabinoid system on executive
functioning have been extensively studied in animal models. In
vitro experiments have indicated a clear role of endocannabinoids
on behavioral flexibility, whereby reduced levels of 2-AG in the
hippocampus resulted in poor flexibility [25,26]. In addition, some
animal studies suggested that endocannabinoids have a negative
impact on set-shifting and cognitive flexibility, and that the use of
antagonists of CB1 receptors can improve such executive functions
[27]. Upregulation of the CB1 receptor, mainly in the prefrontal
cortex, has also been associated with cognitive flexibility
alterations in rats, assessed with attentional set shifting paradigms
(an equivalent to the human Wisconsin card sorting test) [27–29]
and olfactory go/no-go discrimination task [30]. Although the
underling mechanisms remain ambiguous, it has been suggested
that interactions with dopaminergic, GABAergic and glutamater-
gic transmission might be implicated [27,29,30].
In humans, several studies have suggested that acute consump-
tion or administration of exogenous cannabinoid compounds
(namely D9-tetrahydrocannabinol-THC) is associated with exec-
utive impairments. Indeed, acute use of THC in healthy controls is
associated with alterations in response inhibition [31], decision
making [32], and flexibility [33]. Acute administration of low
doses of THC also modulates the cerebral inhibition response
circuits (namely right inferior frontal cortex, anterior cingulate
gyrus and posterior cingulated cortex) during a response inhibition
task [34]. In the same line, after the acute administration of THC
a consistent neural hyperactivity was observed on the prefrontal
and anterior cingulated cortex [35–37], corroborating the
hypothesis of the role of cannabinoids on frontal-mediated
cognitive functions.
Chronic cannabis use has also been associated with executive
functions deficits. Studies examining the degree of inhibitory
control during a Stroop task concluded that cannabis users
produced more errors of commission (failing to inhibit appropri-
ately) than drug-free subjects and also showed an altered pattern of
brain activation (namely reduced left anterior cingulate, bilateral
dorsolateral prefrontal cortex, and right ventromedial prefrontal
cortex activation) [38,39]. Furthermore, dysfunctions in decision
making (assessed with the Iowa Gambling Task) associated with
reduced cortical activation, were observed in chronic cannabis
users compared with non-drug users [40]. These results raise
exciting questions about a plausible role of the endocannabinoid
system on prefrontal-dependent cognitive functions in humans.
However, to date, no published reports establish the impact of the
endocannabinoid system on executive functioning, such as
capacity of inhibition response, impulsivity, or decision making
in humans.
In this study, we explored the relationship between circulating
levels of plasma endocannabinoids (AEA and 2-AG) and executive
functions (decision making, response inhibition, and cognitive
flexibility) in healthy subjects in order to determine the plausible
role of the endocannabinoid system on prefrontal-depended
cognitive functioning. Hence, we used three neuropsychological
tasks (Wisconsin Card Sorting Test; Stroop Color and Word Test;
and Iowa Gambling Task) known to be mediated by prefrontal
and orbitofrontal cortex functioning [17].
Methods
Sample
Seven centers, all involved in the CIBERobn Spanish Research
Network, participated: the Eating Disorders Unit (Department of
Psychiatry, University Hospital of Bellvitge-IDIBELL, Barcelona),
the Department of Endocrinology at the University Hospital of
Santiago (Santiago de Compostela); the Department of Diabetes,
Endocrinology and Nutrition (Clinic University Hospital Virgen
de Victoria, Ma´laga); the Department of Endocrinology (Univer-
sity of Navarra, Pamplona); the Diabetes, Endocrinology and
Endocannabinoids and Executive Functions in Humans
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Nutrition Department, Biomedical Research Institute of Girona
(IdIBGi-Doctor Josep Trueta Hospital, Girona); the IMIM
(Hospital del Mar Medical Research Institute, Barcelona); the
Department of Basic Psychology, Clinic and Psychobiology
(University Jaume I, Castello´). Enrolment in the study was
between January 2010 and September 2012.
One hundred and fifty seven subjects (n = 157) were included.
All participants were female, aged between 18 and 60 years, and
spoke Spanish as their first language. Participants were recruited
through several sources, including word-of-mouth and advertise-
ments in the local university. The lifetime history of health or
mental illnesses profile was based on the general health
questionnaire (GHQ)-28. Prior to assessment, subjects were
specifically asked about lifetime or current presence of drug or
alcohol abuse or dependence (including cannabis abuse/depen-
dence). Sociodemographic characteristics are presented in Table 1.
Exclusion criteria were: (1) Individuals who have suffered a
lifetime disorder of the Axis I mental disorders; (2) History of
chronic medical illness or neurological condition that might affect
cognitive function; (3) Head trauma with loss of consciousness for
more than 2 min, learning disability, or mental retardation; (4)
Use of psychoactive medication or drugs; (5) Being male; and (6)
Age under 18 or over 60 (to discard neuropsychological deficits
associated with age).
All participants were informed about the research procedures
and gave informed consent in writing. Procedures were approved
by the Ethical Committee of each of the aforementioned
institutions.
Neuropsychological Assessment
As described in a previous study [41], all participants underwent
a comprehensive neuropsychological and clinical assessment. The
neuropsychological tests were selected to cover various aspects of
executive functions including decision making, response inhibition,
strategic planning and cognitive flexibility and were administered
by a trained psychologist in a single session and in a randomized
order. All participants were assessed with the following neuropsy-
chological tests: (a) The Wisconsin Card Sorting Test (WCST)
[42], (b) The Stroop Color and Word Test (SCWT) [43] and (c)
The Iowa Gambling Task (IGT) [44]. These tests are well
standardized and clear application norms are included in the
manual, which guarantee the equivalence between administrators.
For two tests (IGT and WCST), a computerized version was
employed, with also help to avoid differences in correction
between administrators. The protocol requires that the adminis-
trator remain unobtrusively present while the administration is
taking place. However, before starting both, the IGT and WCST,
the respondent was told to refrain from asking any questions until
the completion of the test.
(a) Wisconsin card sorting test. The WCST is a classical
measure of cognitive flexibility, conceptualized as the capacity to
shift among stimuli. Subjects have to match a target card by color,
number, or shape with one of four category cards and the
classification rule is unpredictably changing. The test ends when
the participant has completed 6 categories or 128 trials. The main
outcome variable is the number of categories completed and
higher scores indicate better cognitive flexibility and conceptual-
ization. We also considered the number of errors and the number
of cards used until the first category was successfully completed
(initial conceptualization), as both variables are considered
predictors of WCST results and mental set flexibility [45].
(b) Stroop color and word test. This paper and pencil test is
a measure of inhibition response and interference control skills.
Participants have 45 seconds to read as many words as possible in
the first page (color words printed in black ink) and name the ink
in pages 2 (‘‘Xs’’ printed in color) and 3 (names of colors printed in
an incongruent color). The main outcome variable is the
‘‘interference score’’ and higher scores in this variable indicate
better capacity of inhibition response.
(c) Iowa gambling task. This task evaluates decision-
making, risk and reward and punishment value. The subject has
to select 100 cards from four decks (A, B, C and D). After each
card selection an output is given: gain or a gain and loss of money.
For decks A and B the final loss is higher than the final gain, while
decks C and D are advantageous because the punishments are
smaller. The outcome variable is the Total Score, with higher
results point to better performance and higher capacity of decision
making.
Endocannabinoid Quantification Methods
Samples were always collected from subjects between 8 and
9 am after a fast of at least 12 hour duration. Blood obtained from
human volunteers was centrifuged at 3500 rpm at 4uC for 15–
20 min. Plasma aliquots were stored at 280uC until analysis. The
endocannabinoid quantification was done with slight modifica-
tions of a previously described methodology of endocannabinoid
analysis in brain tissue [46]. After the addition of the deuterated
analogues (Cayman Chemical, USA) AEA-d4 (0.5 ng) and 2-AG-
d5 (10 ng) to a 0.5 mL aliquot of plasma, endocannabinoids were
extracted with a liquid-liquid extraction in tert-butyl-methyl-ether
(Merck, Germany) and the extracts analyzed in a LC/MS-MS
system (Agilent 6410, USA). The column used was a C8
(2.16100 mm61.8 mm particle size, Zorbax). The analysis was
done in the multiple reaction monitoring mode (MRM) and the
following precursor to product ion transitions was used: m/z
348R62 for AEA, m/z 352R66 for AEA-d4, m/z
379.2R287 for 2-AG and m/z 384R287 for 2-AG-d5. The
quantification of AEA and 2-AG was done by isotopic dilution.
Variations in accuracy and precision were ,10% for the
individual sample replicates. The limit of detection on column
was 8 pg for AEA and 200 pg for 2-AG.
Table 1. Sociodemographic variables.
Age (years); mean (SD) 25.6 (7.8)
Education level; %
Primary 6.7
Secondary 61.1
University 32.2
Employment status; %
Employed 25.9
Unemployed 7.5
Student 47.6
Student+Employed 19.0
Civil status; %
Single 72.8
Married - in couple 24.5
Divorced - separated 2.7
Tobacco use; %
Yes 31.1
Number of cigarettes-day; mean (SD) 2.3 (4.6)
SD: standard deviation.
doi:10.1371/journal.pone.0066387.t001
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Statistical Analysis
Analyses were carried out with SPSS 20 for Windows. Pearson’s
correlation valued the linear association between endocannabi-
noids on cognitive outcomes. Next, multiple linear regressions
measured the predictive power of endocannabinoids on cognitive
measures. One model was adjusted for each cognitive outcome,
entering simultaneously the two predictors (2-AG and AEA) and
the covariates age, academic level, and tobacco use. The variables
age, academic level, and tobacco use were also included as
covariates into multivariate models since they achieved significant
association with the outcomes (executive functions performance).
R2 coefficients valued the global predictive validity of models.
Results
Table 2 shows the descriptive values for endocannabinoids and
cognitive outcomes. A negative correlation was found between 2-
AG and cognitive flexibility performance. Specifically, there was a
significant inverse correlation between 2-AG and both WCST
total categories completed (r =2.37; p,.05) and WCST trials to
complete the first category (r =2.38; p,.05). A significant positive
correlation was found between AEA concentrations and both,
cognitive flexibility [WCST total categories completed (r = .59;
p,.05); WCST trials to complete the first category (r = .59;
p,.05)] and decision making performance (IGT Total Score;
r = .23; p,.05). We did not found any significant correlation
between either 2-AG (r =2.17) or AEA (r =2.08) concentrations
and Stroop performance.
Following a multiple regression model valuing the specific
contribution of endocannabinoids on executive functions perfor-
mance, 2-AG was significantly and inversely associated with
Stroop interference (p = .05) and WCST performance (WCST
total categories completed; p,.05; WCST trials to complete the
first category; p,.05). 2-AG was not associated with the decision
making performance (p = .28) (see Table 3). A significant
contribution of AEA was also observed on WCST performance
(WCST total categories completed; p,.001; WCST trials to
complete the first category; p,.001). A trend toward significance
was also found on IGT performance (total score; p= .09). AEA
was not a predictor of inhibition response performance (p = .31)
(see Table 3).
Discussion
The primary finding of this study is that the endocannabinoids
AEA and 2-AG have a relevant and opposite role on the executive
functioning in humans. According to our results, elevated levels of
AEA are associated with improvement on decision making and
cognitive flexibility performance, while elevated levels of 2-AG are
associated with disruption of the cognitive flexibility and inhibition
response capacities. These results demonstrate, in humans, the
association between the endocannabinoid system and prefrontal-
depended cognitive functions, and might have implications for the
therapeutic use of drugs with cannabinoid activity.
Our results are in agreement with animal studies that
demonstrate a clear and dose-related role of the endocannabinoid
system in behavioral flexibility [27,29]. Administration of high
doses of CB1 receptor agonists increases impulsive behaviors,
while the administration of low doses of CB1 antagonists improves
set-shifting performance and reduces the number of impulsive
responses [27,47]. Genetic deletion of CB1 receptors also produces
a significant impairment on reversal learning [15,48], in an
analogous way to that found after prefrontal cortex lesions [49]. A
balance between novelty seeking and behavioral inhibition has also
been found using mutant mice lacking the CB1 receptor either in
cortical glutamatergic or GABAergic neurons [50] thus corrobo-
rating the found neural modulation of endocannabinoids on this
executive function.
Our results are also supported by findings in chronic cannabis
users, pointing to long-term and acute effects of the exogenous
agonist of the CB1 receptors (such as derivates of the Cannabis
sativa, namely THC) on executive functioning [51,52]. Specifically,
deficits in cognitive flexibility were reported in chronic cannabis
users [53,54] and seem to be persistent after 28 days of cannabis
abstinence [54]. Impulsive behaviors also characterize the
cognitive profile of cannabis users after both acute and chronic
cannabis use [31,33,51,55], and impairments on decision making
are frequently reported in both recreational and chronic cannabis
users [33,56]. Similarly, it has been demonstrated that, compared
with a placebo, subjects receiving acute administration of THC
make more wrong decisions [33]. Finally, deregulation of the
endocannabinoids system has been found in different psychiatric
and neurologic disorders associated with executive dysfunctions,
such as schizophrenia [57], Alzheimer disease [58], and
Huntington disease [59]. Thus, our results point to a plausible
implication of endocannabinoids on prefrontal cortex-depended
dysfunction in such disorders.
As previously demonstrated in animal studies, the effects of the
endocannabinoid system on executive functions might be
explained by its action on some neurotransmitters, such as
dopamine (DA), glutamate, or GABA, implicated in both
prefrontal activity and executive functioning. In fact, endocanna-
binoids are retrograde messengers and are supposed to play a
relevant role in synapses [60,61]. Depending on the cerebral
regions, the endocannabinoid system might produce activation or
inhibition of neurotransmission, and consequently regulate the
cognitive functions depending on these brain areas, including
executive functions [62–64]. In this line, an enhanced prefrontal
DA activity has been detected after administration of cannabi-
noids, modifying the prefrontal activity by elevating the release of
DA in mesocortical neurons [65,66]. It has also been demonstrat-
ed that the hyperactivity of prefrontal dopaminergic synapses
induced by cannabinoid administration contributes to executive
function deficits [67]. Additionally, CB1 receptor agonist sup-
presses the transmission of glutamate in the prefrontal cortex,
producing impairments on executive functioning [68]. Specifically,
Table 2. Descriptives (mean and standard deviation) for
endocannabinoids and cognitive outcomes.
Mean (SD)
Endocannabinoids
2-arachidonoyl glicerol (ng/mL) 1.60 (1.02)
Arachidonoyl ethanolamide (ng/mL) 0.55 (0.17)
Cognitive variables
STROOP
Interference 5.87 (7.71)
WCST
Total errors 15.65 (13.51)
Categories completed 5.74 (1.18)
Trials first category 15.31 (18.14)
IGT
Total score 17.09 (28.29)
doi:10.1371/journal.pone.0066387.t002
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a disruption in cognitive flexibility was observed after blocking the
NMDA glutamate receptors within the prefrontal cortex [69,70].
Furthermore, it was demonstrated that administration of a CB1
antagonist reduces the CB1 inhibition of glutamatergic activity in
the PFC, which has been associated with activations in the
prefrontal circuits implicated in executive functions [70]. Alto-
gether, a plausible mechanism explaining the modulation of
endocannabinoids on executive functions found in our study might
by their actions on these neurotransmission systems.
Finally, the opposite effect produced by AEA and 2-AG plasma
levels on executive functioning in humans might be explained
because they derive from different biosynthetic pathways. How-
ever, as it has been suggested [5] it is extremely difficult to dissect
AEA from 2-AG function. In addition to the interconnection of
their biosynthetic routes with arachidonic acid metabolism,
neurons have developed mechanisms through which anandamide
and 2-AG can reciprocally control their biosynthesis, possibly as a
way of fine-tuning endocannabinoid tone [5,71,72].
To our knowledge, this is the first study evaluating the role of
endocannabinoids in executive functions in humans. However,
these results must be interpreted in the context of some limitations.
First, measures of intelligence quotient (IQ) were not considered,
which might have influenced the executive performance. None-
theless, years of education, as a cognitive level measure, has been
considered in the statistical analysis. Second, only females were
included in the study, thus the results are not applicable to males.
Considering the sexual dimorphism observed in the endocanna-
binoid system [73], with males having higher levels of CB1
receptors [74] and females displaying a more efficient CB1
receptor activity [75], we decided to focus only on females.
However, replication with a group including males should be
considered. Additionally, cognitive flexibility, decision making,
and inhibition response are complex cognitive functions supported
by complex brain systems, and are hardly explained by only one
task. Thus future studies should consider to include further
decision-making, inhibition response, and cognitive flexibility tasks
in order to better understand such executive variables. Further-
more, we use circulating levels of endocannabinoids, rather than
central concentrations of endocannabinoids, as a measure of
endocannabinoid system functioning. However, because of their
elevated lipophilic characteristics, endocannabinoids easily cross
the blood–brain barrier [76], it is therefore expected that the
plasma levels of the endocannabinoids described in our study are
almost certainly reflecting an equivalent central concentration of
AEA and 2-AG. Finally, although a regression analysis was
performed, our data are correlative in nature, meaning that they
are indicative of associations between parameters and by no means
demonstrate causality. Future studies with a longitudinal design
should be performed in order to confirm the cause-effect
relationships between endocannabinoids and executive functions
in humans.
As a summary, this study demonstrates that, in humans, the
endocannabinoid system plays an important role on prefrontal-
dependent cognitive functioning, probably through mechanisms
involving dopaminergic, cholinergic, GABAergic, and glutama-
tergic systems, as proved in animal models. The present study
might have significant implications for the underlying executive
alterations described in drug users [53,54], obesity [41], and eating
disorders [41,77,78], given the current body of evidence on the
implication of the endocannabinoid system in these disorders [79–
81]. Understanding the neurobiology of their dysexecutive profile
might contribute to the development of new treatments and
pharmacological approaches for these disorders.
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